The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Open accessAbstract
BACKGROUND: Patients with diabetes are at higher risk for death and cardiovascular outcomes than the general population. We investigated whether the excess risk of death and cardiovascular events among patients with type 2 diabetes could be reduced or eliminated. METHODS: In a cohort study, we included 271,174 patients with type 2 diabetes who were registered in the Swedish National Diabetes Register and matched them with 1,355,870 controls on the basis of age, sex, and county. We assessed patients with diabetes according to age categories and according to the presence of five risk factors (elevated glycated hemoglobin level, elevated low-density lipoprotein cholesterol level, albuminuria, smoking, and elevated blood pressure). Cox regression was used to study the excess risk of outcomes (death, acute myocardial infarction, stroke, and hospitalization for heart failure) associated with smoking and the number of variables outside target ranges. We also examined the relationship between various risk factors and cardiovascular outcomes. RESULTS: The median follow-up among all the study participants was 5.7 years, during which 175,345 deaths occurred. Among patients with type 2 diabetes, the excess risk of outcomes decreased stepwise for each risk-factor variable within the target range. Among patients with diabetes who had all five variables within target ranges, the hazard ratio for death from any cause, as compared with controls, was 1.06 (95% confidence interval [CI], 1.00 to 1.12), the hazard ratio for acute myocardial infarction was 0.84 (95% CI, 0.75 to 0.93), and the hazard ratio for stroke was 0.95 (95% CI, 0.84 to 1.07). The risk of hospitalization for heart failure was consistently higher among patients with diabetes than among controls (hazard ratio, 1.45; 95% CI, 1.34 to 1.57). In patients with type 2 diabetes, a glycated hemoglobin level outside the target range was the strongest predictor of stroke and acute myocardial infarction; smoking was the strongest predictor of death. CONCLUSIONS: Patients with type 2 diabetes who had five risk-factor variables within the target ranges appeared to have little or no excess risk of death, myocardial infarction, or stroke, as compared with the general population. (Funded by the Swedish Association of Local Authorities and Regions and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“when all major cardiovascular risk factors are treated to within the target ranges, people with type 2 diabetes have risk of death, MI, or stroke similar to that of the general population (6).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among persons with type 2 diabetes (T2D), cardiovascular risk and mortality are dependent on the number of uncontrolled risk factors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“In addition to the evidence from prospective intervention studies to support comprehensive ASCVD risk factor reduction, a large cohort study confirmed no or only marginally increased mortality, MI, and stroke risk compared with the general population when all major cardiovascular risk factors are managed to goal levels in people with type 2 diabetes (6).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [6]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Hypertriglyceridemia is indirectly linked with changes in HDL-C and LDL-C composition that are conducive to accelerated atherogenesis.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In persons with fasting triglycerides of 200 to 499 mg/dL, despite tight adherence to a healthy diet (to include reduced intake of simple carbohydrates and avoidance of fruit juices and alcohol) and optimized glycemia control, prescribe statin therapy to the maximum tolerated dose to achieve goals for non-HDL-C or apo B, since all apo B–containing particles are potentially atherogenic.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measured
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“To date, aside from icosapent ethyl, fish oil therapy has not been shown to prevent CV adverse events.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“No RCT has yet been reported to investigate the benefit of reducing severe (>500 mg/dL) or moderate (>200 mg/dL) hypertriglyceridemia to prevent CVD.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Despite these newer therapies, the risk of kidney failure remains high, particularly in those whose risk factors are insufficiently controlled.6,7”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredIn the citing paper
“In patients with advanced disease, e.g.T2DM and established microalbuminuria, an intensive, target-driven, multifactorial therapy (Steno-2 study; targets: HbA1c <6.5%, total cholesterol <4.5 mmol/L [175 mg/dL], and BP <130/80 mmHg) resulted in 50% fewer microvascular and macrovascular events after 7.8 years of follow-up.361”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [361]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389
Self-citation
Cited by
Sorted by citations
Items 401–500 of 999
Keys, M. T., Thinggaard, M., Larsen, L. A., Pedersen, D. A., Hallas, J., & Christensen, K. (2022) · International Journal of Epidemiology · doi:10.1093/ije/dyac200 · Cited by 16
Kurtzhals, P., Kreiner, F. F., & Bindra, R. S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110881 · Cited by 20
The current landscape for diabetes treatment: Preventing diabetes-associated CV risk
Dardano, A., Bianchi, C., Garofolo, M., & Prato, S. D. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117560 · Cited by 18
Sweeney, C. M., Ryan, F., Ledwidge, M. T., Ryan, C. A., McDonald, K., Watson, C. J., Pharithi, R. B., & Gallagher, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013015.pub2 · Cited by 16
Nyström, T., Santos‐Pardo, I., Fang, X. L., Cao, Y., Hedberg, F., & JENDLE, J. H. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.58 · Cited by 17
The Importance and Role of Multiple Risk Factor Control in Type 2 Diabetes
Nørgaard, C. H., Mosslemi, M., Lee, C. J., Torp-Pedersen, C. T., & Wong, N. D. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1123-y · Cited by 18
Li, X., Sundquist, J., Forsberg, P.-O., & Sundquist, K. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.04.017 · Cited by 17
de Farias, C. B., Zelmanovitz, T., Coelli, S., Satler, F., Duarte, C. K., Brondani, L. D. A., & Silveiro, S. P. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.10.002 · Cited by 17
Okada, K., Hoshide, S., Kato, M., Kanegae, H., Ishibashi, S., & Kario, K. (2020) · Journal of Clinical Hypertension · doi:10.1111/jch.14131 · Cited by 19
Shin, J., Takada, D., Kunisawa, S., & Imanaka, Y. (2021) · Journal Of Clinical Periodontology · doi:10.1111/jcpe.13441 · Cited by 17
McKay, A. J., Gunn, L. H., Vamos, E. P., Valabhji, J., Molina, G., Molokhia, M., & Majeed, A. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108746 · Cited by 17
Quality and Performance Measurement in Primary Diabetes Care: A Qualitative Study in Urban China
Rasooly, A., Pan, Y., Tang, Z., He, J., Ellen, M., Manor, O., Hu, S., & Davidovitch, N. (2022) · International Journal of Health Policy and Management · doi:10.34172/ijhpm.2022.6372 · Cited by 20
Bucheit, J. D., Ayers, J., Pamulapati, L. G., Browning, A., & Sisson, E. M. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001299 · Cited by 17
The Diabetic Cardiorenal Nexus
D’Elia, J. A., Bayliss, G. P., & Weinrauch, L. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137351 · Cited by 17
Julián, M. T., Alonso, N., Lupón, J., Gavidia‐Bovadilla, G., Ferrer, E., de Antonio, M., López‐Ayerbe, J., Domingo, M., Santiago‐Vacas, E., Zamora, E., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01011-w · Cited by 17
American Heart Association Scientific Sessions 2018
Kurian, M. J., Rentzepis, P. J., Carracher, A. M., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12884 · Cited by 17
Microvascular burden and long-term risk of stroke and dementia in type 2 diabetes mellitus
Liu, Y., Zhao, J., Han, W.-W., Yang, H., Wu, X.-B., Xie, F., Wang, H., Wang, J., Zhao, X., Wan, Z., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.03.053 · Cited by 17
Risk factor reduction in type 2 diabetes demands a multifactorial approach
Rydén, L., Ferrannini, G., & Mellbin, L. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319872015 · Cited by 17
Hospitalization Rates in Older Adults With Albuminuria: The Cardiovascular Health Study
Barzilay, J. I., Bůžková, P., Shlipak, M. G., Bansal, N., Garimella, P. S., & Mukamal, K. J. (2020) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaa020 · Cited by 16
Canto, E. D., Elders, P. J. M., van der Heijden, A. A. W. A., van Ballegooijen, A. J., Lissenberg-Witte, B. I., Rutters, F., & Beulens, J. W. J. (2022) · Diabetologia · doi:10.1007/s00125-022-05826-y · Cited by 16
Hu, Y., Sun, Z., Yu, C., Guo, Y., Pei, P., Yang, L., Chen, Y., Du, H., Sun, D., Pang, Y., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101761 · Cited by 16
Ten reasons gastroenterologists and hepatologists should be treating obesity
Camilleri, M., & El-Omar, E. M. (2023) · Gut · doi:10.1136/gutjnl-2023-329639 · Cited by 18
Heart failure and diabetes: Clinical significance and epidemiology of this two‐way association
Jerkins, T. W., McGill, J. B., & Bell, D. S. H. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15062 · Cited by 19
Liu, Y., Miao, M.-Y., Wang, J., Tang, Q., Han, W.-W., Jia, Y., Tao, H.-W., Zheng, Y., van Dam, R. M., Qin, L., et al. (2023) · Nutrients · doi:10.3390/nu15183910 · Cited by 18
Risk factor control and cardiovascular events in patients with type 2 diabetes mellitus
Song, D. K., Hong, Y. S., Sung, Y., & Lee, H. (2024) · PLoS ONE · doi:10.1371/journal.pone.0299035 · Cited by 19
Effectiveness of a Nutrition Education Program for Patients with Type 2 Diabetes Mellitus
Gortzi, O., Dimopoulou, M., Androutsos, O., Vraka, A., Gousia, H., & Bargiota, Α. (2024) · Applied Sciences · doi:10.3390/app14052114 · Cited by 24
Taimour, S., Avdic, T., Franzén, S., Zarrouk, M., Acosta, S., Nilsson, P. M., Miftaraj, M., Eliasson, B., Svensson, A., & Gottsäter, A. (2019) · Vascular Medicine · doi:10.1177/1358863x19870243 · Cited by 16
Self-citationColeman, R. L., Gray, A. M., Broedl, U. C., FITCHETT, D. H., George, J. T., Woerle, H. J., Zinman, B., & Holman, R. R. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14017 · Cited by 17
Patoulias, D., Katsimardou, A., Kalogirou, M., Zografou, I., Toumpourleka, M., Imprialos, K. P., Stavropoulos, K., Stergiou, I., Papadopoulos, C. E., & Doumas, M. N. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.04.001 · Cited by 15
Chan, K. W., Lee, P. W., Leung, C. P. S., Chan, G. C. W., Yiu, W. H., Cheung, H. M., Ли, Б., Lok, S. W. Y., Li, H., Xue, R., et al. (2020) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-020-02994-5 · Cited by 16
The impact of diabetes on heart failure development: The cardio-renal-metabolic connection
Valensi, P. E., Prévost, G., Pinto, S., Halimi, J., & Donal, E. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108831 · Cited by 18
Montero, A. R., Toro-Tobón, D., Gann, K., Nassar, C. M., Youssef, G. A., & Magee, M. F. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00884-6 · Cited by 20
Fernández‐Rodríguez, R., Martínez‐Vizcaíno, V., Garrido‐Miguel, M., Martínez-Ortega, I. A., Álvarez‐Bueno, C., & Mesas, A. E. (2021) · Nutrition Reviews · doi:10.1093/nutrit/nuab053 · Cited by 17
Барбараш, О. Л., Komarov, A. L., Панченко, Е. П., Староверов, И. И., Shakhnovich, R. M., & Yavelov, I. S. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-4-6-59 · Cited by 16
Choi, I. J., Choo, E. H., Kim, H. J., Lim, S., Moon, D., Lee, K. Y., Hwang, B., Kim, C. J., Park, M., Lee, J. M., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01428-x · Cited by 15
Joundi, R. A., Patten, S. B., Williams, J. V. A., & Smith, E. E. (2022) · International Journal of Stroke · doi:10.1177/17474930211070682 · Cited by 15
Zhang, L., Zhang, J., Qin, Z., Liu, N., Zhang, Z., Lu, Y., Xu, Y., Zhang, J., & Tang, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.813310 · Cited by 15
Khan, M. S., Segar, M. W., Usman, M., Patel, K. V., Spall, H. G. C. V., DeVore, A. D., Vaduganathan, M., Lam, C. S. P., Zannad, F. M., Verma, S., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.03.025 · Cited by 15
Subgroups of adult-onset diabetes: a data-driven cluster analysis in a Ghanaian population
Danquah, I., Mank, I., Hampe, C. S., Meeks, K. A. C., Agyemang, C. O., Owusu‐Dabo, E., Smeeth, L. L., Klipstein‐Grobusch, K., Bahendeka, S., Spranger, J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-37494-2 · Cited by 15
Qin, Y.-N., & Zheng, X. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01165-z · Cited by 16
Avdic, T., Carlsen, H. K., Rawshani, A., Guðbjörnsdóttir, S., Mandalenakis, Z., & Eliasson, B. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02226-x · Cited by 18
Self-citationNISKANEN, L. K., Partonen, T., Auvinen, A. P., & Haukka, J. K. (2020) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2019-213602 · Cited by 15
Patel, K., Gomes, M. B., Charbonnel, B. H., Chen, H., Cid‐Ruzafa, J., Fenici, P., Hammar, N., Ji, L., Kennedy, K. F., Khunti, K., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14180 · Cited by 14
Mekhaimar, M., Dargham, S., El-Shazly, M., Suwaidi, J. A., Jneid, H., & Khalil, C. A. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-10012-6 · Cited by 15
Åkerblom, H., Franzén, S., Zhou, C., Morén, Å., Ottosson, J., Sundbom, M., Eliasson, B., Svensson, A., & Granstam, E. (2021) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.5892 · Cited by 15
Self-citationWatson, C. J., Spiers, P., Waterstone, M., Russell‐Hallinan, A., Gallagher, J., McDonald, K., Ryan, C. A., Gilmer, J. F., & Ledwidge, M. T. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-01860-7 · Cited by 15
Bocchi, E. A., Biolo, A., Moura, L. Z., de Figueiredo, J. A., Montenegro, C. E. L., & de Albuquerque, D. C. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210031 · Cited by 22
Ferrari, F., Scheffel, R. S., Martins, V. M., Santos, R. D., & Stein, R. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00515-4 · Cited by 15
Kim, J. Y., Choi, J., Kim, S. G., & Kim, N. H. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01466-z · Cited by 15
Evidence-Based Cardiovascular Risk Management in Diabetes
Mooradian, A. D. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00336-6 · Cited by 16
Lv, F., Cai, X., Hu, D., Pan, C., Zhang, D., Xu, J., & Ji, L. (2019) · Journal of Diabetes Research · doi:10.1155/2019/5631620 · Cited by 15
Wang, M., Francis, F., Kunz, H., Zhang, X., Wan, C., Liu, Y., Taylor, P., Wild, S. H., & Wu, H. (2022) · Intelligence-Based Medicine · doi:10.1016/j.ibmed.2022.100072 · Cited by 15
Lin, H., Ding, Y., Jia, X., Gu, X., Wang, S., Li, M., Xu, Y. H., Xu, M., Mu, Y., Chen, L., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102212 · Cited by 16
Hasebe, M., Su, C., Keidai, Y., Minamino, H., Yabe, D., Inagaki, N., & Yoshiji, S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70121 · Cited by 16
Awareness and Related Factors of Dyslipidemia in Menopausal Women in Korea
Jeong, J. H., & Kim, M. (2022) · Healthcare · doi:10.3390/healthcare10010112 · Cited by 14
Pandey, A., Khan, M. S., Garcia, K. R., Simpson, F. R., Bahnson, J. L., Patel, K. V., Singh, S., Vaduganathan, M., Bertoni, A. G., Kitzman, D. W., et al. (2022) · The Journals of Gerontology Series A · doi:10.1093/gerona/glac094 · Cited by 13
Cardiac risk stratification of the liver transplant candidate: A comprehensive review
Nagraj, S., Peppas, S., Guerrero, M. G. R., Kokkinidis, D. G., Contreras-Yametti, F., Murthy, S., & Jorde, U. P. (2022) · World Journal of Transplantation · doi:10.5500/wjt.v12.i7.142 · Cited by 14
Maternal Cardiac Changes in Women With Obesity and Gestational Diabetes Mellitus
Thirunavukarasu, S., Ansari, F., Cubbon, R. M., Forbes, K. A., Bucciarelli‐Ducci, C., Newby, D. E., Dweck, M. R., Rider, O. J., Valkovič, L., Rodgers, C. T., et al. (2022) · Diabetes Care · doi:10.2337/dc22-0401 · Cited by 14
Silva-Tinoco, R., Cuatecontzi-Xochitiotzi, T., Bernal-Ceballos, F., de la Torre-Saldaña, V., Galíndez-Fuentes, A. I., & Castillo‐Martínez, L. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.09.002 · Cited by 14
Patel, K. V., Khan, M. S., Segar, M. W., Bahnson, J. L., Garcia, K. R., Clark, J. M., Balasubramanyam, A., Bertoni, A. G., Vaduganathan, M., Farkouh, M. E., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2723 · Cited by 15
Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes
Regan, J. A., Mentz, R. J., Nguyen, M., Green, J. B., Truby, L., Ilkayeva, O., Newgard, C. B., Buse, J. B., Sourij, H., Sjöström, C. D., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.168563 · Cited by 16
Self-citationLi, X., Cai, Z., Yang, F., Wang, Y., Pang, X., Sun, J. Y., Li, X., & Lu, Y. (2024) · Foods · doi:10.3390/foods13020273 · Cited by 15
Developmental pathways and programming of diabetes: epidemiological aspects
Eriksson, J. G. (2019) · Journal of Endocrinology · doi:10.1530/joe-18-0680 · Cited by 15
Ruiz‐García, A., Arranz-Martínez, E., García-Álvarez, J. C., García-Fernández, M. E., Martinez, D., Costa, A. M., de Pablo, C. C., López-Uriarte, B., García-Pliego, R. A., Escuer, P. C., et al. (2019) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.03.006 · Cited by 14
Duan, J., Qian, X., Li, J., Xiao, X., Lu, X., Lv, L., Huang, Q.-Y., Ding, W., Zhang, H., & Xiong, L. (2019) · International Journal of Endocrinology · doi:10.1155/2019/5219782 · Cited by 14
Lindvig, A., Tran, M., Kidd, R., Tikkanen, C. K., & Gæde, P. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1904863 · Cited by 13
Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection
Wu, V. C., Li, Y., & Wang, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137170 · Cited by 15
Sun, Z., Hu, Y., Yu, C., Guo, Y., Pang, Y., Sun, D., Pei, P., Yang, L., Chen, Y., Du, H., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac264 · Cited by 15
Endoplasmic reticulum stress: A common pharmacologic target of cardioprotective drugs
Mooradian, A. D., & Haas, M. J. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175221 · Cited by 14
Brinck, J. W., Hagström, E., Nåtman, J., Franzén, S., Eeg‐Olofsson, K., Nathanson, D., & Eliasson, B. (2022) · Diabetes Care · doi:10.2337/dc22-1025 · Cited by 14
Self-citationSmoking and coronary artery disease risk in patients with diabetes: A Mendelian randomization study
Chen, S., Yang, F., Xu, T., Wang, Y., Zhang, K., Fu, G., & Zhang, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.891947 · Cited by 17
Revisiting the Diabetes-Heart Failure Connection
Wallner, M., Eaton, D., von Lewinski, D., & Sourij, H. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1116-z · Cited by 14
Zargoush, M., Ghazalbash, S., Hosseini, M. M., Alemi, F., & Perri, D. (2025) · Scientific Reports · doi:10.1038/s41598-025-12310-1 · Cited by 13
Dapagliflozin reduces epicardial adipose tissue in patients with heart failure and type 2 diabetes
Alghamdi, M., Dihoum, A., Hakami, K., Bhattacharjee, A., Brown, A. J. M., Singh, J. S., Al-Talabany, S., Lang, C. C., Mordi, I. R., & Khan, F. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70164 · Cited by 14
Salinero-Fort, M. Á., Mostaza-Prieto, J. M., Lahoz, C., Díez, J. I. V., & Cárdenas‐Valladolid, J. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-030344 · Cited by 13
Prediction models of diabetes complications: a scoping review
Ndjaboué, R., Ngueta, G., Rochefort-Brihay, C., Delorme, S., Guay, D., Ivers, N. M., Shah, B. R., Straus, S. E., Yu, C. H. Y., Comeau, S., et al. (2022) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2021-217793 · Cited by 14
Opening the Precision Diabetes Care through Digital Healthcare
Lee, J., Yu, J. S., & Yoon, K. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0386 · Cited by 12
Specific prediction of mortality by oxidative stress‐induced damage to RNA vs. DNA in humans
Jørgensen, A., Brandslund, I., Ellervik, C., Henriksen, T., Weimann, A., Andersen, P. K., & Poulsen, H. E. (2023) · Aging Cell · doi:10.1111/acel.13839 · Cited by 12
Degree of Risk Factor Control and Incident Cardiovascular Diseases in Patients With Hypertension
Kou, M., Wang, X., Ma, H., Li, X., Heianza, Y., & Qi, L. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.05.008 · Cited by 12
Antidiabetic Treatment and Prevention of Ischemic Stroke: A Systematic Review
Prentza, V., Pavlidis, G., Ikonomidis, I., Pililis, S., Lampsas, S., Kountouri, A., Pliouta, L., Korakas, E., Thymis, J., Palaiodimou, L., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195786 · Cited by 14
Zelniker, T. A., & Braunwald, E. (2019) · Cardiac failure review · doi:10.15420/cfr.2018.44.1 · Cited by 13
Diabetes and CVD Risk: Special Considerations in African Americans Related to Care
Wittwer, J. A., Golden, S. H., & Joseph, J. J. (2020) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-020-00648-2 · Cited by 13
Ushigome, E., Kitagawa, N., Kitagawa, N., Tanaka, T., Hasegawa, G., Ohnishi, M., Tsunoda, S., Ushigome, H., Yokota, I., Nakamura, N., et al. (2020) · Hypertension Research · doi:10.1038/s41440-020-00584-z · Cited by 13
Mai, Z., Li, H., Chen, G., Chen, E., Liu, L., Lun, Z., Lai, W., Zhou, C., Yu, S., Liu, J., et al. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07186-y · Cited by 13
Alkhezi, O. S., Alsuhaibani, H. A., Alhadyab, A. A., AlFaifi, M., Alomrani, B., Aldossary, A., & Alfayez, O. M. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.04.005 · Cited by 14
Zhao, Y., Song, P., Yin, S., Fan, T., Li, F., Ge, X., Liu, T., Xu, W., Su, X., & Chen, L. (2023) · Food & Function · doi:10.1039/d2fo02450k · Cited by 13
Longer leukocyte telomere length increases cardiovascular mortality in type 2 diabetes patients
Chen, Z., Shen, Y., He, J., Shen, Y., Zhu, W., Wu, X., & Xiao, M. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13376 · Cited by 13
Dattilo, G., Laterra, G., Licordari, R., Parisi, F., Pistelli, L., Colarusso, L., Zappia, L., Vaccaro, V., Demurtas, E., Allegra, M., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196247 · Cited by 13
Danni, R., Viljanen, A. P. M., Aaronson, A., & Tuuminen, R. (2019) · Acta Ophthalmologica · doi:10.1111/aos.14018 · Cited by 13
Chou, C., Kung, P., Chou, W., & Tsai, W. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-026626 · Cited by 14
Ruiz‐García, A., Arranz-Martínez, E., García-Álvarez, J. C., García-Fernández, M. E., Martinez, D., Costa, A. M., de Pablo, C. C., López-Uriarte, B., García-Pliego, R. A., Escuer, P. C., et al. (2020) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.03.007 · Cited by 13
Increased Mortality Burden in Young Asian Subjects with Dysglycemia and Comorbidities
Rhee, E., Jung, I., Kwon, H., Park, S. E., Kim, Y., Han, K.-D., Park, Y. G., & Lee, W. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041042 · Cited by 13
Igaki, Y., Tanno, M., Sato, T., Kouzu, H., Ogawa, T., Osanami, A., Yano, T., Kuno, A., Miki, T., Nakamura, T., et al. (2021) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2021.01.002 · Cited by 12
Zamani, M. M., Ashtary‐Larky, D., Nosratabadi, S., Bagheri, R., Wong, A., Rafiei, M. M., Asiabar, M. M., Khalili, P., Asbaghi, O., & Davoodi, S. H. (2022) · Phytotherapy Research · doi:10.1002/ptr.7585 · Cited by 12
Silva-Tinoco, R., Cuatecontzi-Xochitiotzi, T., Castillo‐Martínez, L., de la Torre-Saldaña, V., GUZMAN-OLVERA, E. B., & Bernal-Ceballos, F. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.07.004 · Cited by 12
SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus
Lukic, N., Mačvanin, M., Gluvic, Z. M., Rizzo, M., Radak, D. J., Suri, J. S., & Isenović, E. R. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673251493231011192520 · Cited by 14
Samidurai, A., Olex, A. L., Ockaili, R. A., Kraskauskas, D., Roh, S. K., Kukreja, R. C., & Das, A. (2023) · Cells · doi:10.3390/cells12242820 · Cited by 12
Gan, Y., Tian, F., Fan, X., Wang, H. Z., Zhou, J., Yang, N., & Qi, H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1390564 · Cited by 17
Wu, S., Wang, Y., Wang, J., Feng, J. H., Li, F., Lin, L., Ruan, C., Nie, Z., Tian, J., & Jin, C. (2025) · BMC Medicine · doi:10.1186/s12916-025-03923-4 · Cited by 16
Diabetes Mellitus and Long-Term Risk for Heart Failure After Coronary Revascularization
Takeji, Y., Shiomi, H., Morimoto, T., Furukawa, Y., Ehara, N., Nakagawa, Y., Kato, T., Tazaki, J., Kato, E. T., Yaku, H., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-19-0980 · Cited by 12
Metadata
- Authors
- Rawshani, A., Rawshani, A., Franzén, S., Sattar, N., Eliasson, B., Svensson, A.-M., Zethelius, B., Miftaraj, M., McGuire, D. K., Rosengren, A., & Gudbjörnsdottir, S.
- Affiliations
- Uppsala University (SE)
- From the Department of Molecular and Clinical Medicine, Institute of Medicine (Aidin Rawshani, Araz Rawshani, B.E., A. Rosengren, S.G.), and the Health Metrics Unit, Sahlgrenska Academy (S.F.), University of Gothenburg, and the Swedish National Diabetes Register, Center of Registers in Region (Aidin Rawshani, Araz Rawshani, S.F., B.E., A.-M.S., M.M., S.G.), Gothenburg, and the Department of Public Health and Caring Sciences–Geriatrics, Uppsala University, and the Swedish Medical Products Agency,...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-08-16
- Volume
- 379
- Issue
- 7
- Pages
- 633-644
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2887185538
- Cited by
- 1,475
- References
- 22
- Citations by year
- 2026: 158 · 2025: 172 · 2024: 178 · 2023: 175 · 2022: 197 · 2021: 219 · 2020: 210 · 2019: 141 · 2018: 20
- FWCI
- 116.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, cardiovascular risk factors, mortality, acute myocardial infarction, stroke, heart failure hospitalization, HbA1c, LDL cholesterol, albuminuria, smoking, blood pressure, Swedish National Diabetes Register, matched cohort comparison
- MeSH terms
- Adult, Albuminuria, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypercholesterolemia, Hypertension, Male, Middle Aged, Myocardial Infarction, Risk Factors, Smoking, Sweden, Cohort Studies, Body Mass Index, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
